138 related articles for article (PubMed ID: 29507667)
1. Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.
Knapp KA; Pires ES; Adair SJ; Mandal A; Mills AM; Olson WC; Slingluff CL; Parsons JT; Bauer TW; Bullock TN; Herr JC
Oncotarget; 2018 Feb; 9(10):8972-8984. PubMed ID: 29507667
[TBL] [Abstract][Full Text] [Related]
2. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.
Pires ES; D'Souza RS; Needham MA; Herr AK; Jazaeri AA; Li H; Stoler MH; Anderson-Knapp KL; Thomas T; Mandal A; Gougeon A; Flickinger CJ; Bruns DE; Pollok BA; Herr JC
Oncotarget; 2015 Oct; 6(30):30194-211. PubMed ID: 26327203
[TBL] [Abstract][Full Text] [Related]
3. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract][Full Text] [Related]
4. SAS1B protein [ovastacin] shows temporal and spatial restriction to oocytes in several eutherian orders and initiates translation at the primary to secondary follicle transition.
Pires ES; Hlavin C; Macnamara E; Ishola-Gbenla K; Doerwaldt C; Chamberlain C; Klotz K; Herr AK; Khole A; Chertihin O; Curnow E; Feldman SH; Mandal A; Shetty J; Flickinger C; Herr JC
Dev Dyn; 2013 Dec; 242(12):1405-26. PubMed ID: 24038607
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody 7H2.2 binds the C-terminus of the cancer-oocyte antigen SAS1B through the hydrophilic face of a conserved amphipathic helix corresponding to one of only two regions predicted to be ordered.
Legg MSG; Gagnon SML; Powell CJ; Boulanger MJ; Li AJJ; Evans SV
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):623-632. PubMed ID: 35503210
[TBL] [Abstract][Full Text] [Related]
6. The detection of SAS1B in serum provides clues for early diagnosis of thyroid cancer.
Yang HX; Yang Y; Li XD; Miao XM; Yang C; Zhi DF; Su H; Yang G; Gao J; Du CG; Li HJ; Song YL; Cao GF
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1410-1424. PubMed ID: 33629311
[TBL] [Abstract][Full Text] [Related]
7. Oocyte specific oolemmal SAS1B involved in sperm binding through intra-acrosomal SLLP1 during fertilization.
Sachdev M; Mandal A; Mulders S; Digilio LC; Panneerdoss S; Suryavathi V; Pires E; Klotz KL; Hermens L; Herrero MB; Flickinger CJ; van Duin M; Herr JC
Dev Biol; 2012 Mar; 363(1):40-51. PubMed ID: 22206759
[TBL] [Abstract][Full Text] [Related]
8. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.
Pires ES; D'Souza RS; Needham MA; Herr AK; Jazaeri AA; Li H; Stoler MH; Anderson-Knapp KL; Thomas T; Mandal A; Gougeon A; Flickinger CJ; Bruns DE; Pollok BA; Herr JC
Oncotarget; 2017 Feb; 8(9):16099. PubMed ID: 28403580
[No Abstract] [Full Text] [Related]
9. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
10. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
[TBL] [Abstract][Full Text] [Related]
12. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
13. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody.
Aung W; Tsuji AB; Sugyo A; Takashima H; Yasunaga M; Matsumura Y; Higashi T
World J Gastroenterol; 2018 Dec; 24(48):5491-5504. PubMed ID: 30622378
[TBL] [Abstract][Full Text] [Related]
14. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
15. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
[TBL] [Abstract][Full Text] [Related]
16. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
Fujisawa T; Joshi BH; Puri RK
J Transl Med; 2011 Apr; 9():37. PubMed ID: 21477288
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
19. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
20. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
